Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

March 14, 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

March 14, 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.